
    
      This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability
      study performed on 24 healthy adult volunteers and 2 alternates. All 26 subjects completed
      the clinical phase of the study. In each period, subjects were housed from the evening before
      dosing until after the 36-hour blood draw. Single oral 400 mg doses were separated by a
      washout period of 7 days A total of 24 healthy adult volunteers and 2 alternates (17 males
      and 9 non-pregnant females) enrolled in and completed the clinical phase of the study
    
  